# Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease

Study · id `cardio:ct-nct01652872` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01652872](<https://clinicaltrials.gov/study/NCT01652872>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01652872

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 756 participants.

## Technical summary

Registry record NCT01652872. Randomized; triple masking; primary purpose treatment. Start 2012-07-30 (actual); primary completion 2017-10-19 (actual). Results posted on 2018-11-08.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 756 participants (enrolled count; ClinicalTrials.gov record NCT01652872, source copy `cardio:ctgov-nct01652872-2022-09-21`, retrieved 2026-10-26)
- Started: 2012-07-30 (actual) (ClinicalTrials.gov record NCT01652872, source copy `cardio:ctgov-nct01652872-2022-09-21`, retrieved 2026-10-26)
- Primary completion: 2017-10-19 (actual) (ClinicalTrials.gov record NCT01652872, source copy `cardio:ctgov-nct01652872-2022-09-21`, retrieved 2026-10-26)
- Completion: 2017-10-19 (actual) (ClinicalTrials.gov record NCT01652872, source copy `cardio:ctgov-nct01652872-2022-09-21`, retrieved 2026-10-26)
- Results first posted: 2018-11-08 (ClinicalTrials.gov record NCT01652872, source copy `cardio:ctgov-nct01652872-2022-09-21`, retrieved 2026-10-26)
- Countries: United States; Puerto Rico (ClinicalTrials.gov record NCT01652872, source copy `cardio:ctgov-nct01652872-2022-09-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01652872-2022-09-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
- Acronym: START-CKD
- Condition: Anemia in Chronic Kidney Disease Patients Not on Dialysis
- Intervention (Biological): Darbepoetin alfa
- Intervention (Other): Placebo
- Lead sponsor: Amgen
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Amgen (`cardio:org-amgen`)

## Provenance

Content hash: 8453183b1b89a5e35dca86a1217d56888b47a06498b9217987d384e6f3feb74e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
